Details for Patent: 10,039,766
✉ Email this page to a colleague
Which drugs does patent 10,039,766 protect, and when does it expire?
Patent 10,039,766 protects TRUQAP and is included in one NDA.
This patent has eighteen patent family members in fifteen countries.
Summary for Patent: 10,039,766
Title: | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide |
Abstract: | The present invention discloses certain new solid state forms of (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, processes for preparing such forms, pharmaceutical compositions comprising them, and the use of such forms in therapy. |
Inventor(s): | Tomkinson Gary Peter |
Assignee: | AstraZeneca AB |
Application Number: | US15291370 |
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 10,039,766
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-001 | Nov 16, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY | ⤷ Try a Trial | ||||
Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-002 | Nov 16, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,039,766
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2013204533 | ⤷ Try a Trial | |||
Brazil | 112014025586 | ⤷ Try a Trial | |||
Canada | 2869936 | ⤷ Try a Trial | |||
China | 104203953 | ⤷ Try a Trial | |||
European Patent Office | 2847194 | ⤷ Try a Trial | |||
Spain | 2650797 | ⤷ Try a Trial | |||
Hong Kong | 1206337 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |